

## NEWS RELEASE

**HYDERABAD, INDIA (30 October' 2020)** -- SUVEN Pharmaceuticals Limited ("SPL", "Company") today announced unaudited financial results for the quarter and half-year ended 30 September' 2020. The unaudited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 30 October' 2020 at Hyderabad.

### Financial Snapshot

*INR (Millions, except ratios and EPS)*

	Quarter ended			Period ended	
	30-Sep-20	30-Jun-20	30-Sep-19	30-Sep-20	30-Sep-19
Revenue	2,377.45	2,439.72	2,783.73	4,817.16	4,782.09
EBITDA	988.50	1,178.47	1,309.31	2,166.97	2,358.44
EBITDA Margin	41.58%	48.30%	47.03%	44.98%	49.32%
EBIT	913.50	1,107.83	1,253.96	2,021.33	2,248.12
EBIT Margin	38.42%	45.41%	45.05%	41.96%	47.01%
Finance costs	32.63	32.06	39.91	64.69	74.33
Depreciation	75.00	70.63	55.35	145.64	110.32
Taxes	227.57	263.47	314.89	491.04	525.38
Taxes to PBT	25.83%	24.49%	25.94%	25.10%	24.17%
PAT (Standalone)	653.30	812.30	899.16	1,465.60	1,648.41
PAT Margin (Standalone)	27.48%	33.29%	32.30%	30.42%	34.47%
Associate Company	87.53	103.18	35.22	190.70	208.88
PAT (Consolidated)	740.79	915.22	930.05	1,656.01	1,849.09
PAT Margin (Consolidated)	31.16%	37.51%	33.41%	34.38%	38.67%
EPS (Standalore)	2.57	3.19	3.53	5.76	6.48
EPS (Consolidated)	2.91	3.60	3.65	6.51	7.26
Paid up share capital (Re.1/sh)	254.56	127.28	127.28	254.56	127.28

### Growth Ratios

	Quarter ended 30 Sep 20 to Quarter ended 30 Jun 20	Quarter ended 30 Sep 20 to Quarter ended 30 Sep 19	Period ended 30 Sep 20 to Period ended 30 Sep 19
Growth in income	-2.55%	-14.59%	0.73%
Growth in EBITDA	-16.12%	-24.50%	-8.12%
Growth in EBIT	-17.54%	-27.15%	-10.09%
Growth in PAT Standalone	-19.57%	-27.34%	-11.09%
Growth in PAT Consolidated	-19.06%	-20.35%	-10.44%

## Suven Pharmaceuticals Limited

1. The Company is focused on the business of Contract Development and Manufacturing Operations (CDMO).
2. The Board has allotted the Bonus shares at 1:1 ratio in its Board meeting held on 29 September' 2020. Accordingly, the number of shares increased from 12,72,82,478 to 25,45,64,956. In order to maintain uniformity and comparability the EPS of previous periods have been restated. The paid-up capital on account of Bonus issue of Rs.1272.82 Lacs has been appropriated from Share premium account.
3. The Board has approved CAPEX plan of INR 6,000 Million keeping in view of the proposed increase in capacity in Pashamylaram facility, replacement and modernization of production blocks in Suryapet facility, relocation of R&D facilities from Jeedimetla and acquisition of new technologies.
4. On 30 January' 2020, the World Health Organization (WHO) declared the coronavirus (COVID-19) outbreak a "Public Health Emergency of International Concern" and on 11 March' 2020, declared it to be pandemic. Actions taken around the world to help mitigate the spread of the coronavirus include restrictions on travel, quarantines in certain areas and forced closure for certain types of public places and businesses. The actions taken to mitigate the spread expected to continue for more time and may have adverse impact on economics in different geographies in which your Company operates. It is unknown for how long the adverse conditions associated with COVID-19 will last. During this period, the Company has experienced minor disruptions impacting our operations even though there were no major consequences which will materially affect the Company.

**For more information, please visit: <http://www.suvenpharm.com>**

**Risk Statement:**

*Except for historical information, all the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve number of risks and uncertainties. Although Suven Pharmaceuticals attempts to be accurate in making these statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven Pharmaceuticals may not undertake to update any forward-looking statements that may be made from time to time.*

## **Suven Pharmaceuticals Limited**